On April 14, 2022, a working trip to the city of Shymkent took place to inspect the production site of domestic manufacturers and hold a meeting on the medical and pharmaceutical cluster.
Considering measures to restore economic and investment activity in Kazakhstan in the context of the coronavirus pandemic, the Head of State Kassym-Jomart Tokayev emphasized the importance of developing the domestic pharmaceutical industry, stating that by 2025 the country expects to increase the share of its own pharmaceutical production in the country to 50%.
In the implementation of this instruction, the Government approved a comprehensive plan for the development of the pharmaceutical industry until 2025. One of the main directions of the adopted Comprehensive Plan is the development of pharmaceutical science and the creation of new industries with the participation of world players, and the development of domestic production of medicines and medical products.
As part of the activities carried out to support the development of domestic production of pharmaceutical and medical products, the Single Distributor takes the initiative to provide a platform for the entry of large brands into the country from packaging to the full production cycle.
During the working trip, in order to inspect the place, storage conditions of medicines and medical devices, monitoring was carried out at the warehouse of the Single Distributor.
Also, as part of the working trip, to inspect the production site, get acquainted with the range of medicines and medical equipment produced, and discuss the possibility of localization, representatives of the Single Distributor visited the production site of Chimpharm JSC and KAZMEDPRIBOR LLP.
A powerful incentive for the development of domestic production is the development of interaction with the major global pharmaceutical industry from the TOP-50 BigPharma, and the involvement of domestic research institutes, scientific laboratories of large medical universities like R&D centers, as well as their deployment in free economic and industrial zones.
In this regard, it seems appropriate to create pharmaceutical clusters through the involvement of domestic research institutes, scientific laboratories, large medical universities, domestic production sites, the involvement of investment project support institutions, local executive bodies, as well as the deployment of clusters in free economic and industrial zones like R&D centers.
In addition, the production of medical equipment and consumables will be actively developed. The President of the country instructed to expand the volume and range of off-take contracts with domestic producers. These areas are open for investment, and such projects will receive full support from the state.
At the same time, as part of the working trip, the Single Distributor held a meeting with the Akimat of the city of Shymkent on the creation of pharmaceutical clusters in the region by the type of R&D centers.
The meeting participants were presented with state support tools for the development of pharmaceutical clusters. The parties noted that government agencies, science and business should work together on the tasks set and develop in tandem.
It should be recalled that the Single Distributor, with the assistance of the Institute for the Development of the Health Industry of South Korea, held a round table with large Korean pharmaceutical clusters on cooperation in the framework of the creation and development of medical and pharmaceutical clusters between Kazakhstan and South Korea.
Based on the results of the round table, the Single Distributor developed proposals for the elaboration of the production of expensive innovative products, the promotion of the industry in the direction of technology transfer, its digitalization. In particular, the initiative to establish medical-pharmaceutical clusters and developed a top-level structure of clusters in Nur-Sultan, Aktobe and Shymkent.
Following the meeting, the participants noted that the creation of pharmaceutical clusters is a painstaking work that requires the creation of a single platform for the interaction of all involved institutions and companies.
Pharmaceutical cluster is a group of geographically localized interconnected innovative firms - drug developers, manufacturing companies; suppliers of equipment, components, specialized services; infrastructure facilities: research institutes, universities, technology parks, business incubators and other organizations that complement each other and enhance the competitive advantages of individual companies and the cluster.
The most attractive regions for creating pharmaceutical clusters in the republic are the cities of Nursultan, Almaty, Shymkent, as well as the Aktobe region due to the concentration of production sites and leading medical universities on their territory.
This is an important strategic direction that solves several socially significant tasks at once. This is a question of new jobs, raising the level of the scientific base, the transition to GMP standards, the creation of innovative drugs, the popularization of the domestic pharmaceutical industry and, of course, the economic development of the region in which the cluster is being built. Combining the efforts of Kazakhstani companies around the creation of clusters in different regions of the country and investing in their development by both the state and private capital will ensure the growth of import-substituting products and the involvement of foreign companies in the construction of pharmaceutical plants in Kazakhstan.
Along with this, within the framework of a working trip, in order to familiarize with the accounting and remnants of medicines and medical products, with the existing practice of medical equipping, representatives of the Single Distributor visited "City Hospital No. 2.
The parties also discussed problematic issues of medical equipping, its planning, efficiency of use of medical equipment, training of specialists (medical and technical personnel of healthcare organizations), improvement of maintenance and repair.